Effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo
Description
Background: Vitiligo is a common autoimmune disease resulting in skin and hair depigmentation. A cream formulation of the Janus kinase 1/2 inhibitor ruxolitinib induced significant clinical improvement in patients with nonsegmental vitiligo in phase 3 trials, but real-world data are limited. Objective: To evaluate the effectiveness and safety of ruxolitinib cream in Chinese patients with nonsegmental vitiligo. Methods: In this single-center, single-arm, observational, real-word study, patients applied 1.5% ruxolitinib cream twice daily for 24 weeks (maximum dosage, 100 g every 2 weeks). The primary endpoint was a ≥75% improvement from baseline in the Facial Vitiligo Area Scoring Index (F-VASI 75) at week 24. Results: In total, 111 patients were enrolled, 49.5% (95% confidence interval = 39.9–59.2) of whom achieved F-VASI 75 at week 24. The most common adverse events were application-site pruritus (33.3%), application-site acne (31.5%), upper respiratory tract infection (22.5%), and application-site exfoliation (18.9%). Limitations: This study’s limitations included its small sample size and short follow-up period. Conclusion This study highlighted the potential of ruxolitinib cream as a safe and effective therapeutic option for nonsegmental vitiligo in the Chinese population in a real-world setting.